Clinical Publications

TRITON

Macular Choroidal Thickness and the Risk of Referable Diabetic Retinopathy in Type 2 Diabetes: A 2-Year Longitudinal Study

AUTHORS:

Wang W, Li L, Wang J, Chen Y, Kun X, Gong X, Wei D, Wang D, Liang X, Liu H, Huang W

PUBLICATION:

Invest Ophthalmol Vis Sci. 2022; 63(4):9. PMID: 35420642 DOI: 10.1167/iovs.63.4.9

Study Purpose

To evaluate the associations between choroidal thickness (CT) and the 2-year incidence of referable diabetic retinopathy (RDR)

Overview

Study Design

Prospective, longitudinal, cohort study

# of Eyes/
Patients

• 1345 patients with diabetes

Study Device

DRI Triton SS-OCT (Topcon, Tokyo, Japan)

Outcome Measures

• Primary outcome was new-onset RDR at 2 years; defined as patients with NDR, or mild NPDR, and without DME at baseline who developed RDR over the 2-year follow up • Secondary outcome was new-onset DME during the 2-year follow-up

Results

At the 2-year follow-up, 120 (8.92%) of the included patients had newly developed RDR, and seven (0.52%) developed DME.
CT was significantly thinner in patients with new-onset RDR than in non-RDR patients, with an average CT of 166.3+55.6 µm vs 199.3+62.5 µm (P

IMOvifa reduced measurement time by

39%

Conclusions

• The study provides the first longitudinal evidence of the predictive value of choroidal thickness for DR onset and progression. • The study is limited in that the subjects were all Chinese patients with type 2 DM; CT measurements may differ by ethnicity and type of diabetes, so the conclusions should not be generalized to other races. • Automated quantitative assessment of CT using SS-OCT can provide prognostic information about RDR risk in patients with type 2 DM.